Showing results (81-90 of 213) with videos related to
Sort By:
Pageof 22
Experimental Cell Research|September 1, 1993
Phenotypic and cell cycle analysis of human peripheral blood mononuclear cells activated with interleukin-2 and/or OKT3K E Platts, J Lawry, B W Hancock, et al.International Journal of Oncology|February 28, 2012
Primary thyroid lymphoma: the 40 year experience of a UK lymphoma treatment centreM Alzouebi, J R Goepel, J M Horsman, et al.Cancer|February 15, 1984
The effects of radiotherapy on immunity in patients with cured localized carcinoma of the cervix uteriB W Hancock, L Bruce, M D Whitham, et al.Postgraduate Medical Journal|October 1, 1976
Systemic mastocytosis--central nervous system features and lymphographic demonstration of lymph node involvementB W Hancock, P Dandona, D C Cumberland, et al.Thrombosis and Haemostasis|February 28, 1989
Effects of calcium channel blockers on in vitro platelet function in whole blood using single platelet countingT J Walley, K L Woods, D B BarnettLife Sciences|September 12, 1983
The characteristics of adrenoceptors in homogenates of human cerebral cortex labelled by (3H)-rauwolscineR J Summers, D B Barnett, S R NahorskiInternational Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 17, 2004
The clinical presentation, treatment, and outcome of patients diagnosed with possible ectopic molar gestationA M Gillespie, E A Lidbury, J A Tidy, et al.British Journal of Cancer|April 3, 1999
The presentation and management of post-partum choriocarcinomaL S Dobson, A M Gillespie, R E Coleman, et al.British Journal of Cancer|May 2, 2000
Persistent gestational trophoblastic disease: results of MEA (methotrexate, etoposide and dactinomycin) as first-line chemotherapy in high risk disease and EA (etoposide and dactinomycin) as second-line therapy for low risk diseaseL S Dobson, P C Lorigan, R E Coleman, et al.European Journal of Cancer & Clinical Oncology|November 1, 1982
Depressed spontaneous natural killing and interferon augmentation in patients with malignant lymphomaC M Hawrylowicz, R C Rees, B W Hancock, et al.Pageof 22